Utility of p16 immunohistochemistry for the identification of Lynch syndrome

Clinical Cancer Research

Volumn 15, Issue 9, 2009, Pages 3156-3162

  Payá, Artemio ^a   Alenda, Cristina ^a   Pérez Carbonell, Lucía ^a   Rojas, Estefanía ^a   Soto, José Luis ^a   Guillén, Carmen ^a   Castillejo, Adela ^a   Barberá, Victor M ^a   Carrato, Alfredo ^a   Castells, Antoni ^b   Llor, Xavier ^c   Andreu, Montserrat ^e   Koh, Jim ^d   Enders, Greg H ^f   Benlloch, Susana ^a   Jover, Rodrigo ^a,g  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d HOSPITAL DEL MAR   (Spain)

^e UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^f DUKE UNIVERSITY   (United States)

^g FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; PROTEIN MLH1; PROTEIN P16;

ADULT; ARTICLE; CANCER DIAGNOSIS; COLORECTAL CANCER; CONTROLLED STUDY; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENE SILENCING; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GERM-LINE MUTATION; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 65649090603     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3116     Document Type: Article

References (41)

1. Rustgi AK. The genetics of hereditary colon cancer. Genes Dev 2007;21:2525-2538 (Pubitemid 47607664)
2. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993;363:558-561 (Pubitemid 23186645)
3. Jover R, Paya A, Alenda C, et al. Defective mismatch-repair colorectal cancer:clinicopathologic characteristics and usefulness of immunohistochemical analysis for diagnosis. Am J Clin Pathol 2004;122:389-394
4. Pinol V, Castells A, Andreu M, et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005;293:1986-1994.
5. Wheeler JM, Bodmer WF, Mortensen NJ. DNA mismatch repair genes and colorectal cancer. Gut 2000;47:148-153 (Pubitemid 30430425)
6. Jarvinen HJ, Mecklin JP, Sistonen P. Screening reduces colorectal cancer rate in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 1995;108:1405-1411
7. Umar A, Boland CR, Terdiman JP, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261-268
8. Hawkins N, Norrie M, Cheong K, et al. CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology 2002;122:1376-1387
9. Samowitz WS, Albertsen H, Herrick J, et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 2005;129:837-845
10. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 2006;38:787-793
11. Pinol V, Andreu M, Castells A, Paya A, Bessa X, Rodrigo J. Frequency of hereditary non-polyposis colorectal cancer and other colorectal cancer familial forms in Spain:a multicentre, prospective, nationwide study. Eur J Gastroenterol Hepatol 2004;16:39-45. (Pubitemid 39043701)
12. Xicola RM, Llor X, Pons E, et al. Performance of different microsatellite marker panels for detection of mismatch repair-deficient colorectal tumors. J Natl Cancer Inst 2007;99:244-252
13. Dai CY, Furth EE, Mick R, et al. p16(INK4a) expression begins early in human colon neoplasia and correlates inversely with markers of cell proliferation. Gastroenterology 2000;119:929-942
14. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000;28:E32.
15. Fiegl H, Gattringer C, Widschwendter A, et al. Methylated DNA collected by tampons-a new tool to detect endometrial cancer. Cancer Epidemiol Biomarkers Prev 2004;13:882-888
16. Ogino S, Kawasaki T, Brahmandam M, et al. Precision and performance characteristics of bisulfite conversion and real-time PCR (MethyLight) for quantitative DNA methylation analysis. J Mol Diagn 2006;8:209-217
17. Widschwendter M, Siegmund KD, Muller HM, et al. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 2004;64:3807-3813
18. Ogino S, Cantor M, Kawasaki T, et al. CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies. Gut 2006;55:1000-1006
19. Benlloch S, Paya A, Alenda C, et al. Detection of BRAF V600E mutation in colorectal cancer:comparison of automatic sequencing and real-time chemistry methodology. J Mol Diagn 2006;8:540-543
20. Hampel H, Frankel W, Panescu J, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 2006;66:7810-7817
21. Kolodner RD, Tytell JD, Schmeits JL, et al. Germ-line msh6 mutations in colorectal cancer families. Cancer Res 1999;59:5068-5074
22. Wahlberg SS, Schmeits J, Thomas G, et al. Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolyposis colon cancer families. Cancer Res 2002;62:3485-3492
23. Lynch HT, Boland CR, Rodriguez-Bigas MA, Amos C, Lynch JF, Lynch PM. Who should be sent for genetic testing in hereditary colorectal cancer syndromes? J Clin Oncol 2007;25:3534-3542
24. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005;352:1851-1860.
25. Van Lier MG, De Wilt JH, Wagemakers JJ, et al. Underutilization of microsatellite instability analysis in colorectal cancer patients at high risk for Lynch syndrome. Scand J Gastroenterol 2009; Jan 19:1-5. [Epub ahead of print].
26. Popat S, Hubner R, Houlston RS. Systematic review ofmicrosatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-618 (Pubitemid 46224239)
27. Carethers JM, Smith EJ, Behling CA, et al. Use of 5-fluorouracil and survival in patients with microsatellite unstable colorectal cancer. Gastroenterology 2004;126:394-401.
28. Jover R, Zapater P, Castells A, et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 2006;55:848-855
29. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-257
30. Deng G, Bell I, Crawley S, et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated h MLH1, but not inhereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004;10:191-195
31. Wang L, Cunningham JM, Winters JL, et al. BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res 2003;63:5209-5212
32. Bessa X, Balleste B, Andreu M, et al. A prospective, multicenter, population-based study of BRAF mutational analysis for Lynch syndrome screening. Clin Gastroenterol Hepatol 2008;6:206-214
33. Domingo E, Laiho P, Ollikainen M, et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 2004;41:664-668
34. Bettstetter M, Dechant S, Ruemmele P, et al. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR. Clin Cancer Res 2007;13:3221-3228
35. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003;349:2042-2054 (Pubitemid 37448928)
36. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell 2006;127:265-275 (Pubitemid 44572384)
37. Forbes S, Clements J, Dawson E, et al. COSMIC 2005. Br J Cancer 2006;94:318-322
38. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-3229 (Pubitemid 32695003)
39. Gibson SL, Boquoi A, Chen T, Sharpless NE, Brensinger C, Enders GH. p16(Ink4a) inhibits histologic progression and angiogenic signaling in min colon tumors. Cancer Biol Ther 2005;4:1389-1394 (Pubitemid 43131186)
40. Gonzalgo ML, Hayashida T, Bender CM, et al. The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Res 1998;58:1245-1252
41. Nguyen C, Liang G, Nguyen TT, et al. Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J Natl Cancer Inst 2001;93:1465-1472